Sentient Bioscience is developing proprietary technology for embolization therapy and site-specific drug delivery to treat cancer and other serious medical conditions. Embolization therapy involves non-surgical, minimally invasive procedures designed to limit blood supply to benign and cancerous tumors. Materials used to block such blood supply, known as embolics, also serve to deliver drugs to tumors in a more targeted manner as compared to systemic administration. Sentient’s research efforts currently center around novel polymer particles and methods designed to work alone or in combination with drugs and biologics developed by other pharmaceutical and biotech companies.
© 2017 Slater Technology Fund | Contact